Olon Group, a global pharmaceutical CDMO, has announced two key leadership appointments aimed at strengthening its biologics and complex molecule manufacturing services. Jérôme Bédier has been named CEO of Olon’s French entities, while Andrea Conforto will serve as M&S VP
Olon, a global API provider and contract development and manufacturing organization (CDMO), has confirmed the construction timeline for its advanced facility in Rodano, Milan. Dedicated to ultra-potent compounds, the site will reach full-scale production by January 2025. Currently, the small-scale
Antibody-Drug Conjugates (ADCs) – known as ‘the guided missiles of cancer therapy’ – are forecast to drive robust double-digit growth in contract development and manufacturing over the coming years, positioning them as a pivotal force in the biopharmaceutical landscape. ADCs
Olon, a chemical-pharmaceutical group, has announced its intention to acquire HuvePharma Italia Srl and its manufacturing site in Garessio, Cuneo, Italy. The acquisition involves integrating HuvePharma Italia’s operations, including its production site, workforce, and product portfolio, into Olon’s existing network.
Olon SpA Contract Manufacturing & Development (CDMO) Profile Olon S.p.A. is a worldwide leader in the development and production of APIs (Active Pharmaceutical Ingredients), the ideal partner for custom synthesis and contract manufacturing projects. Olon is an Italian Company, with
Olon Group has announced the acquisition of GTP Bioways Group. This move aims to enhance Olon’s capabilities in supporting CDMO biotechnology projects, especially in early-stage molecule development. Paolo Tubertini, CEO of Olon Group, stated, “The acquisition of GTP Bioways Group
Oncology is one of the most important growth markets for the pharmaceuticals industry, partly because of the increasing prevalence of cancer in a world population that is growing and living longer. Ahead of the CDMO Live 2024, Giorgio Bertolini, senior
Antheia, a pharmaceutical ingredient manufacturer transforming essential medicine supply chains, and Olon Group have announced the continuation of their ongoing partnership. This collaboration aims to leverage Olon’s vast fermentation infrastructure to manufacture Antheia’s early products. The partnership between Antheia and Olon
Olon Group, a leading API supplier and contract manufacturer, has announced the construction of a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite in Concord, Ohio. This suite is set to significantly expand Olon’s capabilities to serve clients developing innovative
OLON is a Manufacturer/Innovator, Contract Service, Engineering company operating in the pharmaceutical industry. Olon Group is a global leader in the development and production of active pharmaceutical ingredients for CDMO and Generics, a reliable and preferential partner to the pharmaceutical,
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
